Nalu-0016-3

Nalu-0016-3 is a proprietary small molecule therapeutic candidate being developed by Nalu Bio for the treatment of endometriosis. The drug is part of Nalu Bio's platform of chemistry-based cannabinoids, which focuses on creating high-purity, chemically synthesized cannabinoid and cannabinoid-inspired molecules. These compounds are designed to leverage the therapeutic potential of the endocannabinoid system to address chronic pain and inflammatory conditions without the impurities or psychoactive effects often associated with plant-derived extracts. As of 2024, Nalu-0016-3 is in the IND-enabling phase of development, progressing toward clinical trials for endometriosis-associated symptoms.